nodes	percent_of_prediction	percent_of_DWPC	metapath
Amantadine—ABCB1—peripheral nervous system neoplasm	0.369	1	CbGaD
Amantadine—SLC22A2—Cisplatin—peripheral nervous system neoplasm	0.0513	0.264	CbGbCtD
Amantadine—ABCB1—Topotecan—peripheral nervous system neoplasm	0.0343	0.176	CbGbCtD
Amantadine—ABCB1—Alitretinoin—peripheral nervous system neoplasm	0.0343	0.176	CbGbCtD
Amantadine—ABCB1—Dactinomycin—peripheral nervous system neoplasm	0.0238	0.122	CbGbCtD
Amantadine—ABCB1—Vincristine—peripheral nervous system neoplasm	0.0146	0.0753	CbGbCtD
Amantadine—ABCB1—Cisplatin—peripheral nervous system neoplasm	0.0137	0.0702	CbGbCtD
Amantadine—ABCB1—Etoposide—peripheral nervous system neoplasm	0.0134	0.069	CbGbCtD
Amantadine—ABCB1—Doxorubicin—peripheral nervous system neoplasm	0.00915	0.047	CbGbCtD
Amantadine—GRIN2C—nerve—peripheral nervous system neoplasm	0.00644	0.0828	CbGeAlD
Amantadine—GRIN1—ganglion—peripheral nervous system neoplasm	0.00527	0.0678	CbGeAlD
Amantadine—GRIN2B—nerve—peripheral nervous system neoplasm	0.00509	0.0655	CbGeAlD
Amantadine—GRIN2B—ganglion—peripheral nervous system neoplasm	0.00503	0.0646	CbGeAlD
Amantadine—GRIN2A—nerve—peripheral nervous system neoplasm	0.00445	0.0572	CbGeAlD
Amantadine—GRIN2A—ganglion—peripheral nervous system neoplasm	0.0044	0.0565	CbGeAlD
Amantadine—DDC—nerve—peripheral nervous system neoplasm	0.00416	0.0535	CbGeAlD
Amantadine—DDC—ganglion—peripheral nervous system neoplasm	0.00411	0.0528	CbGeAlD
Amantadine—GRIN2C—brainstem—peripheral nervous system neoplasm	0.00277	0.0355	CbGeAlD
Amantadine—GRIN2D—brainstem—peripheral nervous system neoplasm	0.00257	0.033	CbGeAlD
Amantadine—SLC22A1—ganglion—peripheral nervous system neoplasm	0.00239	0.0307	CbGeAlD
Amantadine—GRIN1—brainstem—peripheral nervous system neoplasm	0.00229	0.0295	CbGeAlD
Amantadine—GRIN2B—brainstem—peripheral nervous system neoplasm	0.00219	0.0281	CbGeAlD
Amantadine—MAOB—nerve—peripheral nervous system neoplasm	0.00214	0.0275	CbGeAlD
Amantadine—MAOB—ganglion—peripheral nervous system neoplasm	0.00211	0.0272	CbGeAlD
Amantadine—GRIN2A—brainstem—peripheral nervous system neoplasm	0.00191	0.0246	CbGeAlD
Amantadine—DRD2—nerve—peripheral nervous system neoplasm	0.00181	0.0232	CbGeAlD
Amantadine—DDC—brainstem—peripheral nervous system neoplasm	0.00179	0.0229	CbGeAlD
Amantadine—DRD2—ganglion—peripheral nervous system neoplasm	0.00178	0.0229	CbGeAlD
Amantadine—SLC22A2—trigeminal ganglion—peripheral nervous system neoplasm	0.00166	0.0214	CbGeAlD
Amantadine—GRIN2C—cerebellum—peripheral nervous system neoplasm	0.00136	0.0175	CbGeAlD
Amantadine—GRIN2D—cerebellum—peripheral nervous system neoplasm	0.00127	0.0163	CbGeAlD
Amantadine—GRIN1—cerebellum—peripheral nervous system neoplasm	0.00113	0.0145	CbGeAlD
Amantadine—SIGMAR1—trigeminal ganglion—peripheral nervous system neoplasm	0.00108	0.0139	CbGeAlD
Amantadine—GRIN2B—cerebellum—peripheral nervous system neoplasm	0.00108	0.0139	CbGeAlD
Amantadine—MAOB—trigeminal ganglion—peripheral nervous system neoplasm	0.00104	0.0133	CbGeAlD
Amantadine—SIGMAR1—parotid gland—peripheral nervous system neoplasm	0.00102	0.0131	CbGeAlD
Amantadine—MAOB—parotid gland—peripheral nervous system neoplasm	0.000979	0.0126	CbGeAlD
Amantadine—GRIN2A—cerebellum—peripheral nervous system neoplasm	0.000942	0.0121	CbGeAlD
Amantadine—MAOB—brainstem—peripheral nervous system neoplasm	0.000918	0.0118	CbGeAlD
Amantadine—DRD2—brainstem—peripheral nervous system neoplasm	0.000775	0.00996	CbGeAlD
Amantadine—SIGMAR1—cerebellum—peripheral nervous system neoplasm	0.000473	0.00608	CbGeAlD
Amantadine—GRIN2D—CREB phosphorylation through the activation of Ras—HRAS—peripheral nervous system neoplasm	0.000467	0.00453	CbGpPWpGaD
Amantadine—GRIN2B—BDNF signaling pathway—NCAM1—peripheral nervous system neoplasm	0.000466	0.00452	CbGpPWpGaD
Amantadine—GRIN2B—Ras activation uopn Ca2+ infux through NMDA receptor—HRAS—peripheral nervous system neoplasm	0.000458	0.00444	CbGpPWpGaD
Amantadine—GRIN2C—Transmission across Chemical Synapses—BCHE—peripheral nervous system neoplasm	0.000457	0.00443	CbGpPWpGaD
Amantadine—MAOB—cerebellum—peripheral nervous system neoplasm	0.000453	0.00582	CbGeAlD
Amantadine—DDC—SIDS Susceptibility Pathways—NTRK2—peripheral nervous system neoplasm	0.000444	0.0043	CbGpPWpGaD
Amantadine—GRIN2D—Transmission across Chemical Synapses—BCHE—peripheral nervous system neoplasm	0.000425	0.00412	CbGpPWpGaD
Amantadine—GRIN2C—Post NMDA receptor activation events—HRAS—peripheral nervous system neoplasm	0.000414	0.00401	CbGpPWpGaD
Amantadine—DDC—SIDS Susceptibility Pathways—TH—peripheral nervous system neoplasm	0.000406	0.00394	CbGpPWpGaD
Amantadine—GRIN1—BDNF signaling pathway—NTRK2—peripheral nervous system neoplasm	0.000406	0.00394	CbGpPWpGaD
Amantadine—GRIN2B—BDNF signaling pathway—NTRK2—peripheral nervous system neoplasm	0.000396	0.00384	CbGpPWpGaD
Amantadine—GRIN2D—Post NMDA receptor activation events—HRAS—peripheral nervous system neoplasm	0.000385	0.00373	CbGpPWpGaD
Amantadine—GRIN2A—CREB phosphorylation through the activation of Ras—HRAS—peripheral nervous system neoplasm	0.000384	0.00372	CbGpPWpGaD
Amantadine—DRD2—cerebellum—peripheral nervous system neoplasm	0.000382	0.00491	CbGeAlD
Amantadine—GRIN2C—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—peripheral nervous system neoplasm	0.000381	0.0037	CbGpPWpGaD
Amantadine—GRIN1—SIDS Susceptibility Pathways—NTRK2—peripheral nervous system neoplasm	0.000381	0.0037	CbGpPWpGaD
Amantadine—ABCB1—trigeminal ganglion—peripheral nervous system neoplasm	0.000378	0.00487	CbGeAlD
Amantadine—GRIN2C—Alzheimers Disease—CASP3—peripheral nervous system neoplasm	0.000368	0.00357	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—CNTN6—peripheral nervous system neoplasm	0.000365	0.00354	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—CNTN6—peripheral nervous system neoplasm	0.000356	0.00345	CbGpPWpGaD
Amantadine—GRIN1—Spinal Cord Injury—BDNF—peripheral nervous system neoplasm	0.000356	0.00345	CbGpPWpGaD
Amantadine—GRIN2D—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—peripheral nervous system neoplasm	0.000354	0.00344	CbGpPWpGaD
Amantadine—GRIN2C—Neuronal System—BCHE—peripheral nervous system neoplasm	0.00035	0.0034	CbGpPWpGaD
Amantadine—DDC—Amino acid and derivative metabolism—TH—peripheral nervous system neoplasm	0.00035	0.00339	CbGpPWpGaD
Amantadine—GRIN1—SIDS Susceptibility Pathways—TH—peripheral nervous system neoplasm	0.000349	0.00339	CbGpPWpGaD
Amantadine—GRIN2A—Transmission across Chemical Synapses—BCHE—peripheral nervous system neoplasm	0.000349	0.00338	CbGpPWpGaD
Amantadine—GRIN2A—Reelin signaling pathway—AKT1—peripheral nervous system neoplasm	0.000349	0.00338	CbGpPWpGaD
Amantadine—GRIN2D—Alzheimers Disease—CASP3—peripheral nervous system neoplasm	0.000342	0.00332	CbGpPWpGaD
Amantadine—GRIN1—CREB phosphorylation through the activation of Ras—HRAS—peripheral nervous system neoplasm	0.000335	0.00325	CbGpPWpGaD
Amantadine—DDC—Circadian rythm related genes—TH—peripheral nervous system neoplasm	0.000332	0.00322	CbGpPWpGaD
Amantadine—GRIN1—BDNF signaling pathway—NTRK1—peripheral nervous system neoplasm	0.000331	0.00321	CbGpPWpGaD
Amantadine—DDC—SIDS Susceptibility Pathways—BDNF—peripheral nervous system neoplasm	0.000331	0.00321	CbGpPWpGaD
Amantadine—GRIN2B—CREB phosphorylation through the activation of Ras—HRAS—peripheral nervous system neoplasm	0.000326	0.00316	CbGpPWpGaD
Amantadine—GRIN2D—Neuronal System—BCHE—peripheral nervous system neoplasm	0.000326	0.00316	CbGpPWpGaD
Amantadine—GRIN2B—BDNF signaling pathway—NTRK1—peripheral nervous system neoplasm	0.000323	0.00313	CbGpPWpGaD
Amantadine—GRIN2A—Post NMDA receptor activation events—HRAS—peripheral nervous system neoplasm	0.000316	0.00306	CbGpPWpGaD
Amantadine—GRIN1—Transmission across Chemical Synapses—BCHE—peripheral nervous system neoplasm	0.000304	0.00295	CbGpPWpGaD
Amantadine—GRIN1—BDNF signaling pathway—BDNF—peripheral nervous system neoplasm	0.000303	0.00294	CbGpPWpGaD
Amantadine—GRIN2B—Transmission across Chemical Synapses—BCHE—peripheral nervous system neoplasm	0.000297	0.00288	CbGpPWpGaD
Amantadine—GRIN2B—Reelin signaling pathway—AKT1—peripheral nervous system neoplasm	0.000296	0.00287	CbGpPWpGaD
Amantadine—GRIN2B—BDNF signaling pathway—BDNF—peripheral nervous system neoplasm	0.000296	0.00287	CbGpPWpGaD
Amantadine—DDC—Circadian rythm related genes—NTRK1—peripheral nervous system neoplasm	0.000295	0.00286	CbGpPWpGaD
Amantadine—GRIN2A—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—peripheral nervous system neoplasm	0.000291	0.00282	CbGpPWpGaD
Amantadine—GRIN1—SIDS Susceptibility Pathways—BDNF—peripheral nervous system neoplasm	0.000284	0.00276	CbGpPWpGaD
Amantadine—GRIN2A—Alzheimers Disease—CASP3—peripheral nervous system neoplasm	0.000281	0.00272	CbGpPWpGaD
Amantadine—GRIN1—Post NMDA receptor activation events—HRAS—peripheral nervous system neoplasm	0.000276	0.00267	CbGpPWpGaD
Amantadine—DDC—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000273	0.00265	CbGpPWpGaD
Amantadine—GRIN2B—Post NMDA receptor activation events—HRAS—peripheral nervous system neoplasm	0.000269	0.0026	CbGpPWpGaD
Amantadine—GRIN2A—Neuronal System—BCHE—peripheral nervous system neoplasm	0.000267	0.00259	CbGpPWpGaD
Amantadine—GRIN1—EPHB-mediated forward signaling—HRAS—peripheral nervous system neoplasm	0.000254	0.00246	CbGpPWpGaD
Amantadine—GRIN1—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—peripheral nervous system neoplasm	0.000254	0.00246	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—NCAM1—peripheral nervous system neoplasm	0.00025	0.00242	CbGpPWpGaD
Amantadine—GRIN2B—EPHB-mediated forward signaling—HRAS—peripheral nervous system neoplasm	0.000247	0.0024	CbGpPWpGaD
Amantadine—GRIN2B—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—peripheral nervous system neoplasm	0.000247	0.0024	CbGpPWpGaD
Amantadine—GRIN1—Alzheimers Disease—CASP3—peripheral nervous system neoplasm	0.000245	0.00237	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—NCAM1—peripheral nervous system neoplasm	0.000243	0.00236	CbGpPWpGaD
Amantadine—Diarrhoea—Tretinoin—peripheral nervous system neoplasm	0.000241	0.000943	CcSEcCtD
Amantadine—Diarrhoea—Isotretinoin—peripheral nervous system neoplasm	0.000241	0.000943	CcSEcCtD
Amantadine—Hypotension—Vincristine—peripheral nervous system neoplasm	0.00024	0.00094	CcSEcCtD
Amantadine—Paraesthesia—Alitretinoin—peripheral nervous system neoplasm	0.00024	0.000938	CcSEcCtD
Amantadine—GRIN2B—Alzheimers Disease—CASP3—peripheral nervous system neoplasm	0.000239	0.00232	CbGpPWpGaD
Amantadine—Renal failure acute—Doxorubicin—peripheral nervous system neoplasm	0.000238	0.000932	CcSEcCtD
Amantadine—Dyspnoea—Alitretinoin—peripheral nervous system neoplasm	0.000238	0.000931	CcSEcCtD
Amantadine—Diarrhoea—Melphalan—peripheral nervous system neoplasm	0.000238	0.000931	CcSEcCtD
Amantadine—Osteoarthritis—Epirubicin—peripheral nervous system neoplasm	0.000237	0.00093	CcSEcCtD
Amantadine—Somnolence—Alitretinoin—peripheral nervous system neoplasm	0.000237	0.000929	CcSEcCtD
Amantadine—Feeling abnormal—Dactinomycin—peripheral nervous system neoplasm	0.000237	0.000928	CcSEcCtD
Amantadine—Anxiety—Cisplatin—peripheral nervous system neoplasm	0.000236	0.000925	CcSEcCtD
Amantadine—GRIN2C—Alzheimers Disease—TP53—peripheral nervous system neoplasm	0.000236	0.00229	CbGpPWpGaD
Amantadine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—peripheral nervous system neoplasm	0.000235	0.000922	CcSEcCtD
Amantadine—Dyspepsia—Alitretinoin—peripheral nervous system neoplasm	0.000235	0.000919	CcSEcCtD
Amantadine—Dizziness—Topotecan—peripheral nervous system neoplasm	0.000235	0.000919	CcSEcCtD
Amantadine—GRIN1—Neuronal System—BCHE—peripheral nervous system neoplasm	0.000233	0.00226	CbGpPWpGaD
Amantadine—Dizziness—Tretinoin—peripheral nervous system neoplasm	0.000233	0.000911	CcSEcCtD
Amantadine—Dizziness—Isotretinoin—peripheral nervous system neoplasm	0.000233	0.000911	CcSEcCtD
Amantadine—Insomnia—Vincristine—peripheral nervous system neoplasm	0.000232	0.00091	CcSEcCtD
Amantadine—Decreased appetite—Alitretinoin—peripheral nervous system neoplasm	0.000232	0.000908	CcSEcCtD
Amantadine—Paraesthesia—Vincristine—peripheral nervous system neoplasm	0.000231	0.000904	CcSEcCtD
Amantadine—Gastrointestinal disorder—Alitretinoin—peripheral nervous system neoplasm	0.00023	0.000902	CcSEcCtD
Amantadine—MAOB—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.00023	0.00223	CbGpPWpGaD
Amantadine—Fatigue—Alitretinoin—peripheral nervous system neoplasm	0.00023	0.000901	CcSEcCtD
Amantadine—Leukopenia—Etoposide—peripheral nervous system neoplasm	0.000228	0.000894	CcSEcCtD
Amantadine—Constipation—Alitretinoin—peripheral nervous system neoplasm	0.000228	0.000893	CcSEcCtD
Amantadine—Body temperature increased—Dactinomycin—peripheral nervous system neoplasm	0.000227	0.000891	CcSEcCtD
Amantadine—GRIN2B—Neuronal System—BCHE—peripheral nervous system neoplasm	0.000227	0.0022	CbGpPWpGaD
Amantadine—Anaphylactic shock—Cisplatin—peripheral nervous system neoplasm	0.000227	0.00089	CcSEcCtD
Amantadine—Oedema—Cisplatin—peripheral nervous system neoplasm	0.000227	0.00089	CcSEcCtD
Amantadine—Cardiac arrest—Epirubicin—peripheral nervous system neoplasm	0.000226	0.000884	CcSEcCtD
Amantadine—Vomiting—Topotecan—peripheral nervous system neoplasm	0.000226	0.000883	CcSEcCtD
Amantadine—Cardiac failure—Doxorubicin—peripheral nervous system neoplasm	0.000225	0.000882	CcSEcCtD
Amantadine—Lethargy—Doxorubicin—peripheral nervous system neoplasm	0.000224	0.000878	CcSEcCtD
Amantadine—Vomiting—Isotretinoin—peripheral nervous system neoplasm	0.000224	0.000876	CcSEcCtD
Amantadine—Vomiting—Tretinoin—peripheral nervous system neoplasm	0.000224	0.000876	CcSEcCtD
Amantadine—Rash—Topotecan—peripheral nervous system neoplasm	0.000224	0.000876	CcSEcCtD
Amantadine—Dermatitis—Topotecan—peripheral nervous system neoplasm	0.000224	0.000875	CcSEcCtD
Amantadine—Decreased appetite—Vincristine—peripheral nervous system neoplasm	0.000223	0.000875	CcSEcCtD
Amantadine—Ataxia—Epirubicin—peripheral nervous system neoplasm	0.000223	0.000874	CcSEcCtD
Amantadine—Nervous system disorder—Cisplatin—peripheral nervous system neoplasm	0.000223	0.000873	CcSEcCtD
Amantadine—Headache—Topotecan—peripheral nervous system neoplasm	0.000222	0.00087	CcSEcCtD
Amantadine—Rash—Isotretinoin—peripheral nervous system neoplasm	0.000222	0.000869	CcSEcCtD
Amantadine—Rash—Tretinoin—peripheral nervous system neoplasm	0.000222	0.000869	CcSEcCtD
Amantadine—Gastrointestinal disorder—Vincristine—peripheral nervous system neoplasm	0.000222	0.000869	CcSEcCtD
Amantadine—Tachycardia—Cisplatin—peripheral nervous system neoplasm	0.000222	0.000869	CcSEcCtD
Amantadine—Dermatitis—Tretinoin—peripheral nervous system neoplasm	0.000222	0.000868	CcSEcCtD
Amantadine—Dermatitis—Isotretinoin—peripheral nervous system neoplasm	0.000222	0.000868	CcSEcCtD
Amantadine—Fatigue—Vincristine—peripheral nervous system neoplasm	0.000222	0.000868	CcSEcCtD
Amantadine—Convulsion—Etoposide—peripheral nervous system neoplasm	0.000221	0.000866	CcSEcCtD
Amantadine—Vomiting—Melphalan—peripheral nervous system neoplasm	0.000221	0.000865	CcSEcCtD
Amantadine—Skin disorder—Cisplatin—peripheral nervous system neoplasm	0.000221	0.000864	CcSEcCtD
Amantadine—Headache—Tretinoin—peripheral nervous system neoplasm	0.00022	0.000863	CcSEcCtD
Amantadine—Headache—Isotretinoin—peripheral nervous system neoplasm	0.00022	0.000863	CcSEcCtD
Amantadine—Hypertension—Etoposide—peripheral nervous system neoplasm	0.00022	0.000862	CcSEcCtD
Amantadine—Feeling abnormal—Alitretinoin—peripheral nervous system neoplasm	0.00022	0.000861	CcSEcCtD
Amantadine—Constipation—Vincristine—peripheral nervous system neoplasm	0.00022	0.000861	CcSEcCtD
Amantadine—Osteoarthritis—Doxorubicin—peripheral nervous system neoplasm	0.00022	0.00086	CcSEcCtD
Amantadine—Hyperhidrosis—Cisplatin—peripheral nervous system neoplasm	0.00022	0.00086	CcSEcCtD
Amantadine—Liver function test abnormal—Epirubicin—peripheral nervous system neoplasm	0.000219	0.000858	CcSEcCtD
Amantadine—GRIN2D—Alzheimers Disease—TP53—peripheral nervous system neoplasm	0.000219	0.00213	CbGpPWpGaD
Amantadine—Rash—Melphalan—peripheral nervous system neoplasm	0.000219	0.000858	CcSEcCtD
Amantadine—Dermatitis—Melphalan—peripheral nervous system neoplasm	0.000219	0.000857	CcSEcCtD
Amantadine—Orthostatic hypotension—Epirubicin—peripheral nervous system neoplasm	0.000217	0.000849	CcSEcCtD
Amantadine—Anorexia—Cisplatin—peripheral nervous system neoplasm	0.000217	0.000848	CcSEcCtD
Amantadine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—peripheral nervous system neoplasm	0.000216	0.000845	CcSEcCtD
Amantadine—Hypotension—Cisplatin—peripheral nervous system neoplasm	0.000212	0.000832	CcSEcCtD
Amantadine—Hypersensitivity—Dactinomycin—peripheral nervous system neoplasm	0.000212	0.00083	CcSEcCtD
Amantadine—GRIN1—BDNF signaling pathway—PTPN11—peripheral nervous system neoplasm	0.000211	0.00205	CbGpPWpGaD
Amantadine—Body temperature increased—Alitretinoin—peripheral nervous system neoplasm	0.000211	0.000826	CcSEcCtD
Amantadine—Nausea—Topotecan—peripheral nervous system neoplasm	0.000211	0.000825	CcSEcCtD
Amantadine—Confusional state—Etoposide—peripheral nervous system neoplasm	0.00021	0.000822	CcSEcCtD
Amantadine—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.000209	0.000819	CcSEcCtD
Amantadine—Nausea—Tretinoin—peripheral nervous system neoplasm	0.000209	0.000819	CcSEcCtD
Amantadine—Cardiac arrest—Doxorubicin—peripheral nervous system neoplasm	0.000209	0.000818	CcSEcCtD
Amantadine—Anaphylactic shock—Etoposide—peripheral nervous system neoplasm	0.000208	0.000815	CcSEcCtD
Amantadine—Ataxia—Doxorubicin—peripheral nervous system neoplasm	0.000207	0.000809	CcSEcCtD
Amantadine—Asthenia—Dactinomycin—peripheral nervous system neoplasm	0.000206	0.000808	CcSEcCtD
Amantadine—Nausea—Melphalan—peripheral nervous system neoplasm	0.000206	0.000808	CcSEcCtD
Amantadine—GRIN2B—BDNF signaling pathway—PTPN11—peripheral nervous system neoplasm	0.000206	0.002	CbGpPWpGaD
Amantadine—Dysphagia—Epirubicin—peripheral nervous system neoplasm	0.000205	0.000804	CcSEcCtD
Amantadine—Paraesthesia—Cisplatin—peripheral nervous system neoplasm	0.000204	0.000799	CcSEcCtD
Amantadine—Tachycardia—Etoposide—peripheral nervous system neoplasm	0.000203	0.000796	CcSEcCtD
Amantadine—Body temperature increased—Vincristine—peripheral nervous system neoplasm	0.000203	0.000796	CcSEcCtD
Amantadine—Liver function test abnormal—Doxorubicin—peripheral nervous system neoplasm	0.000203	0.000794	CcSEcCtD
Amantadine—Dyspnoea—Cisplatin—peripheral nervous system neoplasm	0.000203	0.000793	CcSEcCtD
Amantadine—Skin disorder—Etoposide—peripheral nervous system neoplasm	0.000202	0.000792	CcSEcCtD
Amantadine—Hyperhidrosis—Etoposide—peripheral nervous system neoplasm	0.000201	0.000788	CcSEcCtD
Amantadine—Orthostatic hypotension—Doxorubicin—peripheral nervous system neoplasm	0.000201	0.000786	CcSEcCtD
Amantadine—ABCB1—HIF-1-alpha transcription factor network—SLC2A1—peripheral nervous system neoplasm	0.0002	0.00194	CbGpPWpGaD
Amantadine—Anorexia—Etoposide—peripheral nervous system neoplasm	0.000198	0.000777	CcSEcCtD
Amantadine—Decreased appetite—Cisplatin—peripheral nervous system neoplasm	0.000198	0.000774	CcSEcCtD
Amantadine—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.000197	0.000771	CcSEcCtD
Amantadine—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	0.000197	0.00077	CcSEcCtD
Amantadine—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	0.000196	0.000768	CcSEcCtD
Amantadine—Hypotension—Etoposide—peripheral nervous system neoplasm	0.000195	0.000762	CcSEcCtD
Amantadine—Neutropenia—Epirubicin—peripheral nervous system neoplasm	0.000192	0.000752	CcSEcCtD
Amantadine—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.000191	0.000749	CcSEcCtD
Amantadine—DRD2—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	0.000191	0.00185	CbGpPWpGaD
Amantadine—Dysphagia—Doxorubicin—peripheral nervous system neoplasm	0.00019	0.000744	CcSEcCtD
Amantadine—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	0.000189	0.000742	CcSEcCtD
Amantadine—Pruritus—Alitretinoin—peripheral nervous system neoplasm	0.000189	0.000739	CcSEcCtD
Amantadine—Photosensitivity reaction—Epirubicin—peripheral nervous system neoplasm	0.000187	0.000734	CcSEcCtD
Amantadine—Feeling abnormal—Cisplatin—peripheral nervous system neoplasm	0.000187	0.000733	CcSEcCtD
Amantadine—Paraesthesia—Etoposide—peripheral nervous system neoplasm	0.000187	0.000732	CcSEcCtD
Amantadine—Dyspnoea—Etoposide—peripheral nervous system neoplasm	0.000186	0.000727	CcSEcCtD
Amantadine—Somnolence—Etoposide—peripheral nervous system neoplasm	0.000185	0.000725	CcSEcCtD
Amantadine—DDC—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.000185	0.00179	CbGpPWpGaD
Amantadine—Asthenia—Vincristine—peripheral nervous system neoplasm	0.000184	0.000722	CcSEcCtD
Amantadine—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.000183	0.000716	CcSEcCtD
Amantadine—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.000183	0.000715	CcSEcCtD
Amantadine—Rash—Dactinomycin—peripheral nervous system neoplasm	0.000181	0.00071	CcSEcCtD
Amantadine—Decreased appetite—Etoposide—peripheral nervous system neoplasm	0.000181	0.000709	CcSEcCtD
Amantadine—GRIN2A—Alzheimers Disease—TP53—peripheral nervous system neoplasm	0.00018	0.00175	CbGpPWpGaD
Amantadine—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	0.00018	0.000704	CcSEcCtD
Amantadine—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	0.00018	0.000704	CcSEcCtD
Amantadine—Fatigue—Etoposide—peripheral nervous system neoplasm	0.00018	0.000703	CcSEcCtD
Amantadine—GRIN1—Developmental Biology—NCAM1—peripheral nervous system neoplasm	0.000178	0.00173	CbGpPWpGaD
Amantadine—Constipation—Etoposide—peripheral nervous system neoplasm	0.000178	0.000697	CcSEcCtD
Amantadine—GRIN1—Spinal Cord Injury—CASP3—peripheral nervous system neoplasm	0.000178	0.00172	CbGpPWpGaD
Amantadine—Neutropenia—Doxorubicin—peripheral nervous system neoplasm	0.000178	0.000695	CcSEcCtD
Amantadine—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.000176	0.000691	CcSEcCtD
Amantadine—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.000176	0.000689	CcSEcCtD
Amantadine—GRIN2B—Developmental Biology—NCAM1—peripheral nervous system neoplasm	0.000174	0.00168	CbGpPWpGaD
Amantadine—Photosensitivity reaction—Doxorubicin—peripheral nervous system neoplasm	0.000173	0.000679	CcSEcCtD
Amantadine—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	0.000172	0.000672	CcSEcCtD
Amantadine—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.000171	0.000669	CcSEcCtD
Amantadine—Agranulocytosis—Epirubicin—peripheral nervous system neoplasm	0.000171	0.000669	CcSEcCtD
Amantadine—Dizziness—Vincristine—peripheral nervous system neoplasm	0.00017	0.000666	CcSEcCtD
Amantadine—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.00017	0.000664	CcSEcCtD
Amantadine—Rash—Alitretinoin—peripheral nervous system neoplasm	0.000168	0.000659	CcSEcCtD
Amantadine—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.000168	0.000658	CcSEcCtD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—NME1—peripheral nervous system neoplasm	0.000168	0.00163	CbGpPWpGaD
Amantadine—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	0.000167	0.000656	CcSEcCtD
Amantadine—Headache—Alitretinoin—peripheral nervous system neoplasm	0.000167	0.000654	CcSEcCtD
Amantadine—DDC—SIDS Susceptibility Pathways—CASP3—peripheral nervous system neoplasm	0.000165	0.0016	CbGpPWpGaD
Amantadine—ABCB1—cerebellum—peripheral nervous system neoplasm	0.000165	0.00212	CbGeAlD
Amantadine—Body temperature increased—Etoposide—peripheral nervous system neoplasm	0.000165	0.000645	CcSEcCtD
Amantadine—Vomiting—Vincristine—peripheral nervous system neoplasm	0.000163	0.00064	CcSEcCtD
Amantadine—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.000163	0.000639	CcSEcCtD
Amantadine—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	0.000162	0.000635	CcSEcCtD
Amantadine—Rash—Vincristine—peripheral nervous system neoplasm	0.000162	0.000635	CcSEcCtD
Amantadine—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.000162	0.000634	CcSEcCtD
Amantadine—Oedema peripheral—Epirubicin—peripheral nervous system neoplasm	0.000162	0.000634	CcSEcCtD
Amantadine—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	0.000161	0.000631	CcSEcCtD
Amantadine—Headache—Vincristine—peripheral nervous system neoplasm	0.000161	0.000631	CcSEcCtD
Amantadine—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.000158	0.00062	CcSEcCtD
Amantadine—Visual impairment—Epirubicin—peripheral nervous system neoplasm	0.000158	0.00062	CcSEcCtD
Amantadine—SLC22A2—Transmission across Chemical Synapses—BCHE—peripheral nervous system neoplasm	0.000158	0.00153	CbGpPWpGaD
Amantadine—Agranulocytosis—Doxorubicin—peripheral nervous system neoplasm	0.000158	0.000619	CcSEcCtD
Amantadine—GRIN1—Alzheimers Disease—TP53—peripheral nervous system neoplasm	0.000157	0.00152	CbGpPWpGaD
Amantadine—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	0.000156	0.000609	CcSEcCtD
Amantadine—MAOB—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.000155	0.00151	CbGpPWpGaD
Amantadine—Eye disorder—Epirubicin—peripheral nervous system neoplasm	0.000154	0.000601	CcSEcCtD
Amantadine—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	0.000153	0.000601	CcSEcCtD
Amantadine—GRIN2B—Alzheimers Disease—TP53—peripheral nervous system neoplasm	0.000153	0.00148	CbGpPWpGaD
Amantadine—Nausea—Vincristine—peripheral nervous system neoplasm	0.000153	0.000598	CcSEcCtD
Amantadine—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	0.000152	0.000597	CcSEcCtD
Amantadine—GRIN1—BDNF signaling pathway—CASP3—peripheral nervous system neoplasm	0.000152	0.00147	CbGpPWpGaD
Amantadine—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	0.00015	0.000588	CcSEcCtD
Amantadine—Oedema peripheral—Doxorubicin—peripheral nervous system neoplasm	0.00015	0.000586	CcSEcCtD
Amantadine—Asthenia—Etoposide—peripheral nervous system neoplasm	0.000149	0.000585	CcSEcCtD
Amantadine—Angiopathy—Epirubicin—peripheral nervous system neoplasm	0.000149	0.000584	CcSEcCtD
Amantadine—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	0.000149	0.000583	CcSEcCtD
Amantadine—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000148	0.00058	CcSEcCtD
Amantadine—GRIN2B—BDNF signaling pathway—CASP3—peripheral nervous system neoplasm	0.000148	0.00143	CbGpPWpGaD
Amantadine—SLC22A1—Transmission across Chemical Synapses—BCHE—peripheral nervous system neoplasm	0.000148	0.00143	CbGpPWpGaD
Amantadine—Pruritus—Etoposide—peripheral nervous system neoplasm	0.000147	0.000577	CcSEcCtD
Amantadine—Arrhythmia—Epirubicin—peripheral nervous system neoplasm	0.000147	0.000575	CcSEcCtD
Amantadine—Visual impairment—Doxorubicin—peripheral nervous system neoplasm	0.000146	0.000574	CcSEcCtD
Amantadine—DRD2—GPCR ligand binding—NTS—peripheral nervous system neoplasm	0.000145	0.00141	CbGpPWpGaD
Amantadine—Alopecia—Epirubicin—peripheral nervous system neoplasm	0.000145	0.000568	CcSEcCtD
Amantadine—Vomiting—Cisplatin—peripheral nervous system neoplasm	0.000145	0.000566	CcSEcCtD
Amantadine—Mental disorder—Epirubicin—peripheral nervous system neoplasm	0.000144	0.000564	CcSEcCtD
Amantadine—Rash—Cisplatin—peripheral nervous system neoplasm	0.000143	0.000561	CcSEcCtD
Amantadine—Dermatitis—Cisplatin—peripheral nervous system neoplasm	0.000143	0.000561	CcSEcCtD
Amantadine—Malnutrition—Epirubicin—peripheral nervous system neoplasm	0.000143	0.00056	CcSEcCtD
Amantadine—GRIN2C—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—peripheral nervous system neoplasm	0.000143	0.00138	CbGpPWpGaD
Amantadine—Diarrhoea—Etoposide—peripheral nervous system neoplasm	0.000142	0.000558	CcSEcCtD
Amantadine—GRIN1—SIDS Susceptibility Pathways—CASP3—peripheral nervous system neoplasm	0.000142	0.00138	CbGpPWpGaD
Amantadine—Eye disorder—Doxorubicin—peripheral nervous system neoplasm	0.000142	0.000556	CcSEcCtD
Amantadine—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	0.000141	0.000552	CcSEcCtD
Amantadine—Tension—Epirubicin—peripheral nervous system neoplasm	0.00014	0.00055	CcSEcCtD
Amantadine—DRD2—GPCR ligand binding—CD55—peripheral nervous system neoplasm	0.000139	0.00135	CbGpPWpGaD
Amantadine—Nervousness—Epirubicin—peripheral nervous system neoplasm	0.000139	0.000544	CcSEcCtD
Amantadine—GRIN1—Spinal Cord Injury—MYC—peripheral nervous system neoplasm	0.000139	0.00135	CbGpPWpGaD
Amantadine—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	0.000138	0.00054	CcSEcCtD
Amantadine—Dizziness—Etoposide—peripheral nervous system neoplasm	0.000138	0.000539	CcSEcCtD
Amantadine—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000137	0.000536	CcSEcCtD
Amantadine—Arrhythmia—Doxorubicin—peripheral nervous system neoplasm	0.000136	0.000532	CcSEcCtD
Amantadine—Nausea—Cisplatin—peripheral nervous system neoplasm	0.000135	0.000529	CcSEcCtD
Amantadine—Vision blurred—Epirubicin—peripheral nervous system neoplasm	0.000135	0.000528	CcSEcCtD
Amantadine—Alopecia—Doxorubicin—peripheral nervous system neoplasm	0.000134	0.000526	CcSEcCtD
Amantadine—DDC—Metabolism—GNS—peripheral nervous system neoplasm	0.000134	0.0013	CbGpPWpGaD
Amantadine—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	0.000133	0.000521	CcSEcCtD
Amantadine—GRIN2D—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—peripheral nervous system neoplasm	0.000133	0.00129	CbGpPWpGaD
Amantadine—Vomiting—Etoposide—peripheral nervous system neoplasm	0.000132	0.000518	CcSEcCtD
Amantadine—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	0.000132	0.000518	CcSEcCtD
Amantadine—Agitation—Epirubicin—peripheral nervous system neoplasm	0.000131	0.000515	CcSEcCtD
Amantadine—Rash—Etoposide—peripheral nervous system neoplasm	0.000131	0.000514	CcSEcCtD
Amantadine—Dermatitis—Etoposide—peripheral nervous system neoplasm	0.000131	0.000514	CcSEcCtD
Amantadine—DRD2—Circadian rythm related genes—TH—peripheral nervous system neoplasm	0.000131	0.00127	CbGpPWpGaD
Amantadine—GRIN1—EPH-Ephrin signaling—HRAS—peripheral nervous system neoplasm	0.000131	0.00127	CbGpPWpGaD
Amantadine—Headache—Etoposide—peripheral nervous system neoplasm	0.00013	0.000511	CcSEcCtD
Amantadine—Tension—Doxorubicin—peripheral nervous system neoplasm	0.00013	0.000508	CcSEcCtD
Amantadine—Nervousness—Doxorubicin—peripheral nervous system neoplasm	0.000129	0.000503	CcSEcCtD
Amantadine—DDC—Metabolism—NME1—peripheral nervous system neoplasm	0.000128	0.00124	CbGpPWpGaD
Amantadine—Leukopenia—Epirubicin—peripheral nervous system neoplasm	0.000128	0.000501	CcSEcCtD
Amantadine—GRIN2B—EPH-Ephrin signaling—HRAS—peripheral nervous system neoplasm	0.000127	0.00124	CbGpPWpGaD
Amantadine—Palpitations—Epirubicin—peripheral nervous system neoplasm	0.000126	0.000495	CcSEcCtD
Amantadine—Vision blurred—Doxorubicin—peripheral nervous system neoplasm	0.000125	0.000488	CcSEcCtD
Amantadine—Convulsion—Epirubicin—peripheral nervous system neoplasm	0.000124	0.000485	CcSEcCtD
Amantadine—Nausea—Etoposide—peripheral nervous system neoplasm	0.000124	0.000484	CcSEcCtD
Amantadine—Hypertension—Epirubicin—peripheral nervous system neoplasm	0.000123	0.000483	CcSEcCtD
Amantadine—DDC—Metabolism—COX2—peripheral nervous system neoplasm	0.000123	0.0012	CbGpPWpGaD
Amantadine—SLC22A2—SLC-mediated transmembrane transport—SLC2A1—peripheral nervous system neoplasm	0.000122	0.00119	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000122	0.00118	CbGpPWpGaD
Amantadine—Agitation—Doxorubicin—peripheral nervous system neoplasm	0.000122	0.000476	CcSEcCtD
Amantadine—Anxiety—Epirubicin—peripheral nervous system neoplasm	0.000121	0.000475	CcSEcCtD
Amantadine—SLC22A2—Neuronal System—BCHE—peripheral nervous system neoplasm	0.000121	0.00118	CbGpPWpGaD
Amantadine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	0.000121	0.000473	CcSEcCtD
Amantadine—GRIN1—Axon guidance—MET—peripheral nervous system neoplasm	0.000119	0.00116	CbGpPWpGaD
Amantadine—Dry mouth—Epirubicin—peripheral nervous system neoplasm	0.000119	0.000466	CcSEcCtD
Amantadine—Leukopenia—Doxorubicin—peripheral nervous system neoplasm	0.000118	0.000464	CcSEcCtD
Amantadine—Confusional state—Epirubicin—peripheral nervous system neoplasm	0.000118	0.000461	CcSEcCtD
Amantadine—SLC22A2—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	0.000118	0.00114	CbGpPWpGaD
Amantadine—Palpitations—Doxorubicin—peripheral nervous system neoplasm	0.000117	0.000458	CcSEcCtD
Amantadine—Oedema—Epirubicin—peripheral nervous system neoplasm	0.000117	0.000457	CcSEcCtD
Amantadine—Anaphylactic shock—Epirubicin—peripheral nervous system neoplasm	0.000117	0.000457	CcSEcCtD
Amantadine—DRD2—Circadian rythm related genes—NTRK1—peripheral nervous system neoplasm	0.000116	0.00113	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—MET—peripheral nervous system neoplasm	0.000116	0.00113	CbGpPWpGaD
Amantadine—Convulsion—Doxorubicin—peripheral nervous system neoplasm	0.000115	0.000449	CcSEcCtD
Amantadine—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	0.000114	0.000448	CcSEcCtD
Amantadine—Hypertension—Doxorubicin—peripheral nervous system neoplasm	0.000114	0.000447	CcSEcCtD
Amantadine—SLC22A1—SLC-mediated transmembrane transport—SLC2A1—peripheral nervous system neoplasm	0.000114	0.00111	CbGpPWpGaD
Amantadine—GRIN1—Spinal Cord Injury—TP53—peripheral nervous system neoplasm	0.000114	0.0011	CbGpPWpGaD
Amantadine—Tachycardia—Epirubicin—peripheral nervous system neoplasm	0.000114	0.000446	CcSEcCtD
Amantadine—SLC22A1—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000114	0.0011	CbGpPWpGaD
Amantadine—Skin disorder—Epirubicin—peripheral nervous system neoplasm	0.000113	0.000444	CcSEcCtD
Amantadine—SLC22A1—Neuronal System—BCHE—peripheral nervous system neoplasm	0.000113	0.0011	CbGpPWpGaD
Amantadine—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	0.000113	0.000442	CcSEcCtD
Amantadine—MAOB—Metabolism—GNS—peripheral nervous system neoplasm	0.000112	0.00109	CbGpPWpGaD
Amantadine—Anxiety—Doxorubicin—peripheral nervous system neoplasm	0.000112	0.00044	CcSEcCtD
Amantadine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	0.000112	0.000438	CcSEcCtD
Amantadine—Anorexia—Epirubicin—peripheral nervous system neoplasm	0.000111	0.000436	CcSEcCtD
Amantadine—GRIN1—Axon guidance—PTPN11—peripheral nervous system neoplasm	0.00011	0.00107	CbGpPWpGaD
Amantadine—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	0.00011	0.000431	CcSEcCtD
Amantadine—SLC22A1—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	0.00011	0.00106	CbGpPWpGaD
Amantadine—Hypotension—Epirubicin—peripheral nervous system neoplasm	0.000109	0.000427	CcSEcCtD
Amantadine—GRIN2A—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—peripheral nervous system neoplasm	0.000109	0.00106	CbGpPWpGaD
Amantadine—Confusional state—Doxorubicin—peripheral nervous system neoplasm	0.000109	0.000426	CcSEcCtD
Amantadine—Oedema—Doxorubicin—peripheral nervous system neoplasm	0.000108	0.000423	CcSEcCtD
Amantadine—Anaphylactic shock—Doxorubicin—peripheral nervous system neoplasm	0.000108	0.000423	CcSEcCtD
Amantadine—MAOB—Metabolism—NME1—peripheral nervous system neoplasm	0.000108	0.00105	CbGpPWpGaD
Amantadine—DRD2—G alpha (i) signalling events—KNG1—peripheral nervous system neoplasm	0.000108	0.00104	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—PTPN11—peripheral nervous system neoplasm	0.000108	0.00104	CbGpPWpGaD
Amantadine—GRIN2C—Transmission across Chemical Synapses—HRAS—peripheral nervous system neoplasm	0.000107	0.00104	CbGpPWpGaD
Amantadine—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	0.000106	0.000415	CcSEcCtD
Amantadine—Insomnia—Epirubicin—peripheral nervous system neoplasm	0.000106	0.000413	CcSEcCtD
Amantadine—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	0.000105	0.000413	CcSEcCtD
Amantadine—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	0.000105	0.000411	CcSEcCtD
Amantadine—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	0.000105	0.00041	CcSEcCtD
Amantadine—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	0.000104	0.000409	CcSEcCtD
Amantadine—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	0.000104	0.000407	CcSEcCtD
Amantadine—Somnolence—Epirubicin—peripheral nervous system neoplasm	0.000104	0.000406	CcSEcCtD
Amantadine—MAOB—Metabolism—COX2—peripheral nervous system neoplasm	0.000104	0.00101	CbGpPWpGaD
Amantadine—Anorexia—Doxorubicin—peripheral nervous system neoplasm	0.000103	0.000403	CcSEcCtD
Amantadine—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	0.000103	0.000402	CcSEcCtD
Amantadine—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	0.000101	0.000397	CcSEcCtD
Amantadine—Hypotension—Doxorubicin—peripheral nervous system neoplasm	0.000101	0.000395	CcSEcCtD
Amantadine—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000101	0.000395	CcSEcCtD
Amantadine—Fatigue—Epirubicin—peripheral nervous system neoplasm	0.000101	0.000394	CcSEcCtD
Amantadine—Constipation—Epirubicin—peripheral nervous system neoplasm	9.98e-05	0.000391	CcSEcCtD
Amantadine—GRIN2D—Transmission across Chemical Synapses—HRAS—peripheral nervous system neoplasm	9.97e-05	0.000967	CbGpPWpGaD
Amantadine—Insomnia—Doxorubicin—peripheral nervous system neoplasm	9.77e-05	0.000382	CcSEcCtD
Amantadine—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	9.7e-05	0.00038	CcSEcCtD
Amantadine—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	9.63e-05	0.000377	CcSEcCtD
Amantadine—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	9.62e-05	0.000377	CcSEcCtD
Amantadine—Somnolence—Doxorubicin—peripheral nervous system neoplasm	9.6e-05	0.000376	CcSEcCtD
Amantadine—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	9.51e-05	0.000372	CcSEcCtD
Amantadine—GRIN1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—peripheral nervous system neoplasm	9.5e-05	0.000921	CbGpPWpGaD
Amantadine—DRD2—G alpha (i) signalling events—GNAS—peripheral nervous system neoplasm	9.42e-05	0.000914	CbGpPWpGaD
Amantadine—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	9.39e-05	0.000368	CcSEcCtD
Amantadine—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	9.32e-05	0.000365	CcSEcCtD
Amantadine—Fatigue—Doxorubicin—peripheral nervous system neoplasm	9.31e-05	0.000365	CcSEcCtD
Amantadine—GRIN1—BDNF signaling pathway—HRAS—peripheral nervous system neoplasm	9.29e-05	0.000901	CbGpPWpGaD
Amantadine—GRIN2B—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—peripheral nervous system neoplasm	9.26e-05	0.000898	CbGpPWpGaD
Amantadine—Constipation—Doxorubicin—peripheral nervous system neoplasm	9.24e-05	0.000362	CcSEcCtD
Amantadine—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	9.23e-05	0.000361	CcSEcCtD
Amantadine—GRIN2B—BDNF signaling pathway—HRAS—peripheral nervous system neoplasm	9.06e-05	0.000878	CbGpPWpGaD
Amantadine—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	8.9e-05	0.000348	CcSEcCtD
Amantadine—GRIN1—Axon guidance—ERBB2—peripheral nervous system neoplasm	8.72e-05	0.000846	CbGpPWpGaD
Amantadine—DDC—Circadian rythm related genes—TP53—peripheral nervous system neoplasm	8.66e-05	0.00084	CbGpPWpGaD
Amantadine—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	8.6e-05	0.000337	CcSEcCtD
Amantadine—DRD2—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	8.57e-05	0.000831	CbGpPWpGaD
Amantadine—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	8.54e-05	0.000334	CcSEcCtD
Amantadine—GRIN1—Developmental Biology—MET—peripheral nervous system neoplasm	8.52e-05	0.000826	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—ERBB2—peripheral nervous system neoplasm	8.51e-05	0.000825	CbGpPWpGaD
Amantadine—Asthenia—Epirubicin—peripheral nervous system neoplasm	8.37e-05	0.000328	CcSEcCtD
Amantadine—GRIN2B—Developmental Biology—MET—peripheral nervous system neoplasm	8.3e-05	0.000805	CbGpPWpGaD
Amantadine—Pruritus—Epirubicin—peripheral nervous system neoplasm	8.26e-05	0.000323	CcSEcCtD
Amantadine—SLC22A2—Metabolism—HSD17B12—peripheral nervous system neoplasm	8.25e-05	0.0008	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—peripheral nervous system neoplasm	8.23e-05	0.000798	CbGpPWpGaD
Amantadine—GRIN2C—Neuronal System—HRAS—peripheral nervous system neoplasm	8.22e-05	0.000797	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	8.21e-05	0.000796	CbGpPWpGaD
Amantadine—GRIN1—BDNF signaling pathway—AKT1—peripheral nervous system neoplasm	8.2e-05	0.000795	CbGpPWpGaD
Amantadine—GRIN2A—Transmission across Chemical Synapses—HRAS—peripheral nervous system neoplasm	8.19e-05	0.000794	CbGpPWpGaD
Amantadine—DDC—Metabolism—ENO2—peripheral nervous system neoplasm	8.09e-05	0.000785	CbGpPWpGaD
Amantadine—GRIN2B—BDNF signaling pathway—AKT1—peripheral nervous system neoplasm	8e-05	0.000775	CbGpPWpGaD
Amantadine—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	7.99e-05	0.000313	CcSEcCtD
Amantadine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—peripheral nervous system neoplasm	7.96e-05	0.000772	CbGpPWpGaD
Amantadine—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	7.96e-05	0.000312	CcSEcCtD
Amantadine—GRIN1—Developmental Biology—PTPN11—peripheral nervous system neoplasm	7.88e-05	0.000764	CbGpPWpGaD
Amantadine—Asthenia—Doxorubicin—peripheral nervous system neoplasm	7.75e-05	0.000303	CcSEcCtD
Amantadine—Dizziness—Epirubicin—peripheral nervous system neoplasm	7.72e-05	0.000302	CcSEcCtD
Amantadine—SLC22A1—Metabolism—HSD17B12—peripheral nervous system neoplasm	7.69e-05	0.000746	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—PTPN11—peripheral nervous system neoplasm	7.68e-05	0.000745	CbGpPWpGaD
Amantadine—GRIN2D—Neuronal System—HRAS—peripheral nervous system neoplasm	7.64e-05	0.000741	CbGpPWpGaD
Amantadine—Pruritus—Doxorubicin—peripheral nervous system neoplasm	7.64e-05	0.000299	CcSEcCtD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—NTRK1—peripheral nervous system neoplasm	7.5e-05	0.000728	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—NTS—peripheral nervous system neoplasm	7.45e-05	0.000723	CbGpPWpGaD
Amantadine—Vomiting—Epirubicin—peripheral nervous system neoplasm	7.42e-05	0.000291	CcSEcCtD
Amantadine—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	7.39e-05	0.000289	CcSEcCtD
Amantadine—Rash—Epirubicin—peripheral nervous system neoplasm	7.36e-05	0.000288	CcSEcCtD
Amantadine—Dermatitis—Epirubicin—peripheral nervous system neoplasm	7.35e-05	0.000288	CcSEcCtD
Amantadine—Headache—Epirubicin—peripheral nervous system neoplasm	7.31e-05	0.000286	CcSEcCtD
Amantadine—DRD2—Signaling by GPCR—CD55—peripheral nervous system neoplasm	7.14e-05	0.000693	CbGpPWpGaD
Amantadine—GRIN1—Transmission across Chemical Synapses—HRAS—peripheral nervous system neoplasm	7.14e-05	0.000693	CbGpPWpGaD
Amantadine—Dizziness—Doxorubicin—peripheral nervous system neoplasm	7.14e-05	0.00028	CcSEcCtD
Amantadine—GRIN2B—Transmission across Chemical Synapses—HRAS—peripheral nervous system neoplasm	6.96e-05	0.000675	CbGpPWpGaD
Amantadine—ABCB1—Allograft Rejection—CASP3—peripheral nervous system neoplasm	6.96e-05	0.000674	CbGpPWpGaD
Amantadine—Nausea—Epirubicin—peripheral nervous system neoplasm	6.93e-05	0.000271	CcSEcCtD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—peripheral nervous system neoplasm	6.87e-05	0.000666	CbGpPWpGaD
Amantadine—Vomiting—Doxorubicin—peripheral nervous system neoplasm	6.87e-05	0.000269	CcSEcCtD
Amantadine—DDC—Metabolism—BCHE—peripheral nervous system neoplasm	6.84e-05	0.000663	CbGpPWpGaD
Amantadine—MAOB—Metabolism—ENO2—peripheral nervous system neoplasm	6.81e-05	0.00066	CbGpPWpGaD
Amantadine—Rash—Doxorubicin—peripheral nervous system neoplasm	6.81e-05	0.000267	CcSEcCtD
Amantadine—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	6.8e-05	0.000266	CcSEcCtD
Amantadine—Headache—Doxorubicin—peripheral nervous system neoplasm	6.77e-05	0.000265	CcSEcCtD
Amantadine—ABCB1—Metabolism—PPIP5K2—peripheral nervous system neoplasm	6.67e-05	0.000647	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—NRAS—peripheral nervous system neoplasm	6.64e-05	0.000644	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	6.53e-05	0.000633	CbGpPWpGaD
Amantadine—DDC—Metabolism—SLC2A1—peripheral nervous system neoplasm	6.52e-05	0.000632	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—NRAS—peripheral nervous system neoplasm	6.47e-05	0.000627	CbGpPWpGaD
Amantadine—DDC—Metabolism—TH—peripheral nervous system neoplasm	6.43e-05	0.000623	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	6.42e-05	0.000623	CbGpPWpGaD
Amantadine—Nausea—Doxorubicin—peripheral nervous system neoplasm	6.41e-05	0.000251	CcSEcCtD
Amantadine—GRIN2A—Neuronal System—HRAS—peripheral nervous system neoplasm	6.27e-05	0.000608	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—ERBB2—peripheral nervous system neoplasm	6.23e-05	0.000604	CbGpPWpGaD
Amantadine—SLC22A2—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	6.22e-05	0.000603	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	6.22e-05	0.000603	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—ERBB2—peripheral nervous system neoplasm	6.07e-05	0.000589	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—GNS—peripheral nervous system neoplasm	5.97e-05	0.000578	CbGpPWpGaD
Amantadine—SLC22A1—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	5.8e-05	0.000562	CbGpPWpGaD
Amantadine—MAOB—Metabolism—BCHE—peripheral nervous system neoplasm	5.75e-05	0.000558	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—NME1—peripheral nervous system neoplasm	5.72e-05	0.000555	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	5.71e-05	0.000553	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—VIP—peripheral nervous system neoplasm	5.65e-05	0.000548	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—GNS—peripheral nervous system neoplasm	5.56e-05	0.000539	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—COX2—peripheral nervous system neoplasm	5.51e-05	0.000534	CbGpPWpGaD
Amantadine—MAOB—Metabolism—SLC2A1—peripheral nervous system neoplasm	5.49e-05	0.000532	CbGpPWpGaD
Amantadine—GRIN1—Neuronal System—HRAS—peripheral nervous system neoplasm	5.47e-05	0.000531	CbGpPWpGaD
Amantadine—MAOB—Metabolism—TH—peripheral nervous system neoplasm	5.41e-05	0.000525	CbGpPWpGaD
Amantadine—GRIN2B—Neuronal System—HRAS—peripheral nervous system neoplasm	5.34e-05	0.000517	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—NME1—peripheral nervous system neoplasm	5.33e-05	0.000517	CbGpPWpGaD
Amantadine—DDC—Metabolism—GNAS—peripheral nervous system neoplasm	5.25e-05	0.000509	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	5.21e-05	0.000505	CbGpPWpGaD
Amantadine—DDC—Metabolism—ABCB1—peripheral nervous system neoplasm	5.15e-05	0.000499	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—COX2—peripheral nervous system neoplasm	5.13e-05	0.000498	CbGpPWpGaD
Amantadine—SLC22A2—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	5e-05	0.000485	CbGpPWpGaD
Amantadine—SLC22A2—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	4.91e-05	0.000476	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—HRAS—peripheral nervous system neoplasm	4.86e-05	0.000471	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—NRAS—peripheral nervous system neoplasm	4.74e-05	0.000459	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—HRAS—peripheral nervous system neoplasm	4.73e-05	0.000459	CbGpPWpGaD
Amantadine—SLC22A1—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	4.66e-05	0.000452	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—NRAS—peripheral nervous system neoplasm	4.62e-05	0.000448	CbGpPWpGaD
Amantadine—SLC22A1—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	4.58e-05	0.000444	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—HSD17B12—peripheral nervous system neoplasm	4.51e-05	0.000437	CbGpPWpGaD
Amantadine—MAOB—Metabolism—GNAS—peripheral nervous system neoplasm	4.42e-05	0.000428	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—NTS—peripheral nervous system neoplasm	4.4e-05	0.000427	CbGpPWpGaD
Amantadine—ABCB1—HIF-1-alpha transcription factor network—AKT1—peripheral nervous system neoplasm	4.35e-05	0.000422	CbGpPWpGaD
Amantadine—MAOB—Metabolism—ABCB1—peripheral nervous system neoplasm	4.33e-05	0.00042	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CD55—peripheral nervous system neoplasm	4.22e-05	0.000409	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—peripheral nervous system neoplasm	3.78e-05	0.000367	CbGpPWpGaD
Amantadine—SLC22A2—Transmission across Chemical Synapses—HRAS—peripheral nervous system neoplasm	3.71e-05	0.00036	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	3.69e-05	0.000358	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—ENO2—peripheral nervous system neoplasm	3.61e-05	0.00035	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—HRAS—peripheral nervous system neoplasm	3.47e-05	0.000336	CbGpPWpGaD
Amantadine—SLC22A1—Transmission across Chemical Synapses—HRAS—peripheral nervous system neoplasm	3.46e-05	0.000336	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—peripheral nervous system neoplasm	3.43e-05	0.000333	CbGpPWpGaD
Amantadine—DRD2—Circadian rythm related genes—TP53—peripheral nervous system neoplasm	3.41e-05	0.000331	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	3.4e-05	0.000329	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—HRAS—peripheral nervous system neoplasm	3.38e-05	0.000328	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—ENO2—peripheral nervous system neoplasm	3.37e-05	0.000327	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	3.35e-05	0.000325	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—VIP—peripheral nervous system neoplasm	3.34e-05	0.000323	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—GNS—peripheral nervous system neoplasm	3.26e-05	0.000316	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	3.22e-05	0.000313	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—NME1—peripheral nervous system neoplasm	3.12e-05	0.000303	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	3.08e-05	0.000299	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—AKT1—peripheral nervous system neoplasm	3.06e-05	0.000297	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—BCHE—peripheral nervous system neoplasm	3.05e-05	0.000296	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—COX2—peripheral nervous system neoplasm	3.01e-05	0.000292	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—AKT1—peripheral nervous system neoplasm	2.98e-05	0.000289	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	2.93e-05	0.000284	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—SLC2A1—peripheral nervous system neoplasm	2.91e-05	0.000282	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—TH—peripheral nervous system neoplasm	2.87e-05	0.000278	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—BCHE—peripheral nervous system neoplasm	2.85e-05	0.000276	CbGpPWpGaD
Amantadine—SLC22A2—Neuronal System—HRAS—peripheral nervous system neoplasm	2.85e-05	0.000276	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	2.73e-05	0.000265	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—SLC2A1—peripheral nervous system neoplasm	2.72e-05	0.000263	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	2.68e-05	0.00026	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—TH—peripheral nervous system neoplasm	2.68e-05	0.000259	CbGpPWpGaD
Amantadine—SLC22A1—Neuronal System—HRAS—peripheral nervous system neoplasm	2.65e-05	0.000257	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—GNAS—peripheral nervous system neoplasm	2.34e-05	0.000227	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	2.31e-05	0.000224	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—ABCB1—peripheral nervous system neoplasm	2.3e-05	0.000223	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	2.2e-05	0.000213	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—GNAS—peripheral nervous system neoplasm	2.18e-05	0.000212	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—ABCB1—peripheral nervous system neoplasm	2.14e-05	0.000208	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	2.03e-05	0.000197	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—KNG1—peripheral nervous system neoplasm	1.98e-05	0.000192	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—ENO2—peripheral nervous system neoplasm	1.97e-05	0.000191	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	1.89e-05	0.000183	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	1.86e-05	0.00018	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—GNAS—peripheral nervous system neoplasm	1.73e-05	0.000168	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—BCHE—peripheral nervous system neoplasm	1.67e-05	0.000162	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.59e-05	0.000154	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—TH—peripheral nervous system neoplasm	1.57e-05	0.000152	CbGpPWpGaD
Amantadine—DDC—Metabolism—AKT1—peripheral nervous system neoplasm	1.42e-05	0.000137	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—GNAS—peripheral nervous system neoplasm	1.28e-05	0.000124	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	1.22e-05	0.000119	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.2e-05	0.000117	CbGpPWpGaD
Amantadine—MAOB—Metabolism—AKT1—peripheral nervous system neoplasm	1.19e-05	0.000116	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	9.5e-06	9.21e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	8.95e-06	8.68e-05	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	8.7e-06	8.44e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CASP3—peripheral nervous system neoplasm	8.62e-06	8.36e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	7.9e-06	7.66e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—NRAS—peripheral nervous system neoplasm	7.23e-06	7.01e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—MYC—peripheral nervous system neoplasm	6.73e-06	6.53e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—AKT1—peripheral nervous system neoplasm	6.33e-06	6.13e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—AKT1—peripheral nervous system neoplasm	5.9e-06	5.72e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—TP53—peripheral nervous system neoplasm	5.53e-06	5.36e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—HRAS—peripheral nervous system neoplasm	5.29e-06	5.13e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—AKT1—peripheral nervous system neoplasm	4.67e-06	4.53e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—AKT1—peripheral nervous system neoplasm	3.46e-06	3.35e-05	CbGpPWpGaD
